{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:07:28Z","timestamp":1768295248787,"version":"3.49.0"},"reference-count":103,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.1080\/14656566.2024.2391526","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T04:41:01Z","timestamp":1724042461000},"page":"1427-1438","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what\u2019s new on the horizon?"],"prefix":"10.1080","volume":"25","author":[{"given":"Katherine","family":"Regling","sequence":"first","affiliation":[{"name":"Pediatric Hematology Oncology, Children\u2019s Hospital of Michigan, Detroit, MI, USA"},{"name":"Department of Pediatrics, Central Michigan University College of Medicine, Mount Pleasant, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert F.","family":"Sidonio","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology, Emory University and Aflac Cancer and Blood Disorders, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14804"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12008"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2019-0022"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108788"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13243"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12119"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1779485"},{"key":"e_1_3_5_12_1","unstructured":"Products Licensed in the US [Internet]. National bleeding disorders foundation. 2024 [cited 2024 Apr 15]. Available from: https:\/\/hemophilia.org\/healthcare-professionals\/guidelines-on-care\/products-licensed-in-the-us#3"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16186"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613227"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077263"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13064"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1616060"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000065"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14970"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102334"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.9.1901.1901"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35897-0"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1581922"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102530"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S389241"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1722864"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000389"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03975.x"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04923.x"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12689"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017418"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13250"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14050"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2243386"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02583.x"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13451"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462085"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1607440"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.01.001"},{"key":"e_1_3_5_43_1","unstructured":"Clinical study to investigate the efficacy and safety of wilate during prophylaxis in Previously treated patients with VWD [Internet]. [cited 2024 Apr 24]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04052698"},{"key":"e_1_3_5_44_1","unstructured":"Bleeding incidence in VWD patients undergoing on-demand treatment [internet]. [cited 2024 Apr 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04053699"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011742"},{"key":"e_1_3_5_46_1","unstructured":"Voncento\u00ae Prescribing Information [Internet]. [cited 2024 Apr 24]. Available from: https:\/\/www.voncento.co.uk\/hcp\/dosing-and-administration"},{"key":"e_1_3_5_47_1","unstructured":"Study of a pd VWF\/FVIII concentrate Biostate\u00ae in subjects with Von Willebrand Disease [Internet]. [cited 2024 Apr 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00941616"},{"key":"e_1_3_5_48_1","unstructured":"Study of Biostate\u00ae in Children with Von Willebrand Disease [Internet]. [cited 2024 Apr 24]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01213446"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000568"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S236789"},{"key":"e_1_3_5_51_1","unstructured":"Extension Study of Biostate in Subjects With Von Willebrand Disease [Internet]. [cited 2024 Apr 25]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01224808"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S268907"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.2450\/2020.0246-20"},{"key":"e_1_3_5_54_1","unstructured":"Study of Voncento\u00ae in Subjects With Von Willebrand Disease [Internet]. [cited 2024 Apr 25]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02552576"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14868"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"e_1_3_5_57_1","unstructured":"A phase 3 open-label interventional study of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-xten fusion protein Efanesoctocog Alfa (BIVV001) in patients with severe hemophilia a (XTEND-1) [Internet]. [cited 2024 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04161495"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_3_5_59_1","unstructured":"Safety efficacy and PK of BIVV001 in pediatric patients with hemophilia a (XTEND-Kids) [Internet]. [cited 2024 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04759131"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01866-9"},{"key":"e_1_3_5_61_1","unstructured":"Press release: FDA approves once-weekly ALTUVIIIOTM a new class of factor VIII therapy for hemophilia a that offers significant bleed protection. Sanofi; [Internet]. 2023; Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-02-23-21-00-00-2614759"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312611"},{"key":"e_1_3_5_63_1","unstructured":"To assess the pharmacokinetics and safety and tolerability of Efanesoctocog Alfa (BIVV001)in adults with type 2N and 3 Von Willebrand disease (VWD) [Internet]. [cited 2024 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04770935"},{"key":"e_1_3_5_64_1","unstructured":"The Clinical Trials Arena Team. Pipeline moves: phase I trial completion in blood disorder. Clinical Trials Arena [Internet]. [cited 2023 May 16]. Available from: https:\/\/www.clinicaltrialsarena.com\/features\/pipeline-moves-hengrui-medicine-triple-negative-breast-cancer\/?cf-view"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27238593"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279948"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024055"},{"key":"e_1_3_5_68_1","unstructured":"BT200 in Hereditary Bleeding Disorders [Internet]. [cited 2024 Apr 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04677803"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016571"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007805"},{"key":"e_1_3_5_71_1","unstructured":"A Pilot crossover trial of prophylactic wilate compared to placebo for heavy menstrual bleeding in patients with VWD (EMPOWER) [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06205095"},{"key":"e_1_3_5_72_1","unstructured":"Efficacy PK immunogenicity and safety of wilate in severe Von Willebrand disease (VWD) patients <6 years of age [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04953884"},{"key":"e_1_3_5_73_1","unstructured":"Efficacy and safety of Fanhdi\u00ae a high-purity Von Willebrand containing FVIII concentrate in pediatric patients with Von Willebrand Disease [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02472665"},{"key":"e_1_3_5_74_1","unstructured":"A study with Optivate\u00ae in people with Von Willebrand disease [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00387192"},{"key":"e_1_3_5_75_1","unstructured":"A study of recombinant Von Willebrand factor (rVWF) with or without ADVATE in children with severe Von Willebrand disease (VWD) [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02932618"},{"key":"e_1_3_5_76_1","unstructured":"Efficacy of alphanate FVIII\/VWF concentrate in type 3 Von Willebrand patients [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00555555"},{"key":"e_1_3_5_77_1","unstructured":"Optivate in People With Von Willebrand Disease Undergoing Surgery [Internet]. [cited 2024 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00404300"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_5_79_1","unstructured":"FDA approves emicizumab-kxwh for hemophilia a with or without factor VIII inhibitors. US Food & Drug Administration; 2018."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000656"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14209"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14491"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14450"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000001298"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14272"},{"key":"e_1_3_5_86_1","unstructured":"Emicizumab for severe Von Willebrand disease (VWD) and VWD\/Hemophilia a (BCDI-XII) [Internet]. [cited 2024 Apr 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05500807"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122817"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15682"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102181"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100545"},{"key":"e_1_3_5_92_1","unstructured":"Our pipeline: preventing the full spectrum of bleeding and thrombotic events [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/hemab.com\/"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000364"},{"key":"e_1_3_5_95_1","unstructured":"The safety and tolerability of SerpinPC in healthy men and in men with severe blood disorders (haemophilia A and B) [Internet]. [cited 2024 May 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04073498"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170245"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-10-0732"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847"},{"issue":"1","key":"e_1_3_5_99_1","first-page":"67","article-title":"Tissue factor pathway inhibitor; its structure, function and clinical significance","volume":"48","author":"Kato H","year":"1996","unstructured":"Kato H. Tissue factor pathway inhibitor; its structure, function and clinical significance. Pol J Pharmacol. 1996;48(1):67\u201372.","journal-title":"Pol J Pharmacol"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00284-2"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00037-6"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12438"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018956"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2391526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T06:03:43Z","timestamp":1729577023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2391526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,7,23]]}},"alternative-id":["10.1080\/14656566.2024.2391526"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2391526","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}